|
|
|
Prostate Clinical Trials |
|
Thank you for your interest in clinical trials for Prostate
Please click "Search" to find Prostate clinical trials and medical research studies.
If you receive too many study listings you may enter your zip code to find the locations closest to you.
|
|
|
|
|
Results from Clinical Connection:
|
|
Your Search Returned No Results. |
|
|
|
|
|
Results from other databases:
|
|
Your search returned over 250 results. The top 250 results are being displayed. Please use
additional keywords or decrease the search distance. |
|
Your search returned 250 studies:
- [F-18]-Fluorodeoxyglucose (FDG) Positron Emission Tomography and Computed Tomography (PET-CT) in Metastatic Prostate Cancer - NCT00282906-90033
Conditions: Prostate Cancer
Location: Los Angeles, CA
- 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer - NCT00859781-10021
Conditions: Prostate Cancer
Location: New York, NY
- 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors - NCT00967577-10021
Conditions: Kidney Cancer - Head and Neck Cancer - Breast Cancer - Non-small Cell Lung Cancer - Colorectal Cancer - Pancreatic Cancer - Ovarian Cancer - Esophageal Cancer - Gliomas
Location: New York, NY
- 3T Endorectal Magnetic Resonance Spectroscopic Imaging (MRSI) of Prostate - NCT00429338-77030
Conditions: Prostate Cancer
Location: Houston, TX
- 3T Perfluorocarbon-Filled Endorectal Magnetic Resonance Spectroscopic Imaging of Prostate - NCT00464724-77030
Conditions: Prostate Cancer
Location: Houston, TX
- 5-Alpha Reductase and Anabolic Effects of Testosterone - NCT00475501-32608
Conditions: Male Hypogonadism - Muscle Atrophy - Prostate Enlargement - Sarcopenia
Location: Gainesville, FL
- A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer - NCT00663832-10017
Conditions: Prostate Cancer
Location: New York, NY
- A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer - NCT00663832-48201
Conditions: Prostate Cancer
Location: Detroit, MI
- A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer - NCT00663832-63110
Conditions: Prostate Cancer
Location: St. Louis, MO
- A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer - NCT00663832-89135
Conditions: Prostate Cancer
Location: Las Vegas, NV
- A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer - NCT00663832-97239
Conditions: Prostate Cancer
Location: Portland, OR
- A Multicenter Clinical Study of the Sonablate® 500 (SB-500) for the Treatment of Localized (T1c/T2a) Prostate Cancer With HIFU - NCT00770822-
Conditions: Prostate Cancer
Location: Madison, WI
- A Multicenter Clinical Study of the Sonablate® 500 (SB-500) for the Treatment of Locally Recurrent Prostate Cancer With HIFU - NCT00772317-
Conditions: Recurrent Prostate Cancer
Location: Madison, WI
- A Multicenter Clinical Study of the Sonablate® 500 (SB-500) for the Treatment of Locally Recurrent Prostate Cancer With HIFU - NCT00772317-10016
Conditions: Recurrent Prostate Cancer
Location: New York, NY
- A Multicenter Clinical Study of the Sonablate® 500 (SB-500) for the Treatment of Locally Recurrent Prostate Cancer With HIFU - NCT00772317-20307
Conditions: Recurrent Prostate Cancer
Location: Washington, DC
- A Multicenter Clinical Study of the Sonablate® 500 (SB-500) for the Treatment of Locally Recurrent Prostate Cancer With HIFU - NCT00772317-29572
Conditions: Recurrent Prostate Cancer
Location: Myrtle Beach, SC
- A Multicenter Clinical Study of the Sonablate® 500 (SB-500) for the Treatment of Locally Recurrent Prostate Cancer With HIFU - NCT00772317-34102
Conditions: Recurrent Prostate Cancer
Location: Naples, FL
- A Multicenter Clinical Study of the Sonablate® 500 (SB-500) for the Treatment of Locally Recurrent Prostate Cancer With HIFU - NCT00772317-37209
Conditions: Recurrent Prostate Cancer
Location: Nashville, TN
- A Natural History Study of Patients Receiving High-Dose Rate Brachytherapy - NCT00924027-20892
Conditions: Cervical Cancer - Endometrial Cancer - Esophageal Cancer - Prostate Cancer - Biliary Cancer
Location: Bethesda, MD
- A Phase I/II Study of HE3235 in Patients With Prostate Cancer - NCT00716794-10065
Conditions: Prostate Cancer
Location: New York, NY
- A Phase I/II Study of HE3235 in Patients With Prostate Cancer - NCT00716794-78229
Conditions: Prostate Cancer
Location: San Antonio, TX
- A Phase I/II Study of HE3235 in Patients With Prostate Cancer - NCT00716794-92024
Conditions: Prostate Cancer
Location: Encinitas, CA
- A Phase I/II Study of HE3235 in Patients With Prostate Cancer - NCT00716794-94115
Conditions: Prostate Cancer
Location: San Francisco, CA
- A Phase I/II Study of HE3235 in Patients With Prostate Cancer - NCT00716794-95661
Conditions: Prostate Cancer
Location: Roseville, CA
- A Phase I/II Study of HE3235 in Patients With Prostate Cancer - NCT00716794-98109
Conditions: Prostate Cancer
Location: Seattle, WA
- A Phase I/II Trial of 2-Deoxyglucose (2DG) for the Treatment of Advanced Cancer and Hormone Refractory Prostate Cancer - NCT00633087-08901
Conditions: Prostate Cancer
Location: New Brunswick, NJ
- A Phase II Trial of Combination Therapy With Celecoxib and Taxotere for the Treatment of Stage D3 Prostate Cancer - NCT00215345-07018
Conditions: Prostate Cancer
Location: East Orange, NJ
- A Phase III Intensity Radiotherapy Dose Escalation for Prostate Cancer Using Hypofractionation - NCT00667888-77030
Conditions: Prostate Cancer
Location: Houston, TX
- A Phase III Study of Alpharadin (Radium-223)in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases - NCT00699751-70112
Conditions: Hormone Refractory Prostate Cancer - Bone Metastases
Location: New Orleans, LA
- A Phase III Trial of ZD4054 (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer - NCT00617669-
Conditions: Prostate Cancer
Location: Milwaukee, WI
- A Phase III Trial of ZD4054 (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer - NCT00626548-
Conditions: Prostate Cancer
Location: Milwaukee, WI
- A Pilot Study of Physical Activity for Improving Quality of Life in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT) - NCT00853164-63108
Conditions: Prostate Cancer
Location: Saint Louis, MO
- A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer - NCT00972309-20892
Conditions: Prostatic Neoplasms - Prostate Specific Antigens
Location: Bethesda, MD
- A QT/QTc and Multi-Dose Pharmacokinetic (PK) Study of Abiraterone Acetate - NCT00910754-14263
Conditions: Metastatic Castration-Resistant Prostate Cancer
Location: Buffalo, NY
- A QT/QTc and Multi-Dose Pharmacokinetic (PK) Study of Abiraterone Acetate - NCT00910754-29572
Conditions: Metastatic Castration-Resistant Prostate Cancer
Location: Myrtle Beach, SC
- A QT/QTc and Multi-Dose Pharmacokinetic (PK) Study of Abiraterone Acetate - NCT00910754-78229
Conditions: Metastatic Castration-Resistant Prostate Cancer
Location: San Antonio, TX
- A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia. - NCT00855582-50266
Conditions: Erectile Dysfunction - Benign Prostatic Hyperplasia
Location: West Des Moines, IA
- A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia. - NCT00855582-55455
Conditions: Erectile Dysfunction - Benign Prostatic Hyperplasia
Location: Minneapolis, MN
- A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia. - NCT00855582-59802
Conditions: Erectile Dysfunction - Benign Prostatic Hyperplasia
Location: Missoula, MT
- A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia. - NCT00855582-61801
Conditions: Erectile Dysfunction - Benign Prostatic Hyperplasia
Location: Urbana, IL
- A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia. - NCT00855582-73034
Conditions: Erectile Dysfunction - Benign Prostatic Hyperplasia
Location: Edmond, OK
- A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia. - NCT00855582-75231
Conditions: Erectile Dysfunction - Benign Prostatic Hyperplasia
Location: Dallas, TX
- A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia. - NCT00855582-78229
Conditions: Erectile Dysfunction - Benign Prostatic Hyperplasia
Location: San Antonio, TX
- A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia. - NCT00855582-80113
Conditions: Erectile Dysfunction - Benign Prostatic Hyperplasia
Location: Englewood, CO
- A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia. - NCT00855582-85050
Conditions: Erectile Dysfunction - Benign Prostatic Hyperplasia
Location: Phoenix, AZ
- A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia. - NCT00855582-90017
Conditions: Erectile Dysfunction - Benign Prostatic Hyperplasia
Location: Los Angeles, CA
- A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia. - NCT00855582-91356
Conditions: Erectile Dysfunction - Benign Prostatic Hyperplasia
Location: Tarzana, CA
- A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia. - NCT00855582-91942
Conditions: Erectile Dysfunction - Benign Prostatic Hyperplasia
Location: La Mesa, CA
- A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia. - NCT00855582-92120
Conditions: Erectile Dysfunction - Benign Prostatic Hyperplasia
Location: San Diego, CA
- A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia. - NCT00855582-92660
Conditions: Erectile Dysfunction - Benign Prostatic Hyperplasia
Location: Newport Beach, CA
- A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia. - NCT00855582-98043
Conditions: Erectile Dysfunction - Benign Prostatic Hyperplasia
Location: Mountlake Terrace, WA
- A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia. - NCT00855582-99202
Conditions: Erectile Dysfunction - Benign Prostatic Hyperplasia
Location: Spokane, WA
- A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia. - NCT00855582-99508
Conditions: Erectile Dysfunction - Benign Prostatic Hyperplasia
Location: Anchorage, AK
- A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer - NCT00642018-38138
Conditions: Prostate Cancer
Location: Memphis, TN
- A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer - NCT00401765-
Conditions: Prostatic Neoplasms
Location: Nashville, TN
- A Study of Degarelix in Patients With Prostate Cancer - NCT00928434-
Conditions: Prostate Cancer
Location: Seattle, WA
- A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer - NCT00218205-07018
Conditions: Prostate Cancer
Location: East Orange, NJ
- A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer - NCT00672009-90048
Conditions: Prostatic Diseases - Genital Neoplasms, Male - Urogenital Neoplasms - Genital Diseases, Male - Adenocarcinoma - Prostatic Neoplasms - Neoplasms, Glandular and Epithelial - Carcinoma
Location: Los Angeles, CA
- A Study Of the Effectiveness Of Pomegranate Pills in Men With Prostate Cancer Before Prostatectomy - NCT00719030-21231
Conditions: Prostate Cancer
Location: Baltimore, MD
- A Study Of the Effectiveness Of Pomegranate Pills in Men With Prostate Cancer Before Prostatectomy - NCT00719030-27710
Conditions: Prostate Cancer
Location: Durham, NC
- A Study Of the Effectiveness Of Pomegranate Pills in Men With Prostate Cancer Before Prostatectomy - NCT00719030-90095
Conditions: Prostate Cancer
Location: Los Angeles, CA
- A Study of the Safety and Efficacy of Single-agent CNTO 888 (an Anti CC-Chemokine Ligand 2 [CCL2]) in Patients With Metastatic Prostate Cancer - NCT00992186-
Conditions: Prostate Cancer
Location: Charleston, SC
- A Study of V934/V935 in Cancer Patients With Selected Solid Tumors (Merck) - NCT00753415-19104
Conditions: Non-Small Cell Lung - Breast Cancer - Melanoma - Upper GI Tract Carcinoma - Colon Carcinoma - Renal Cell Carcinoma - Bladder Carcinoma - Prostate Cancer
Location: Philadelphia, PA
- A Study of V934/V935 in Cancer Patients With Selected Solid Tumors (Merck) - NCT00753415-33136
Conditions: Non-Small Cell Lung - Breast Cancer - Melanoma - Upper GI Tract Carcinoma - Colon Carcinoma - Renal Cell Carcinoma - Bladder Carcinoma - Prostate Cancer
Location: Miami, FL
- A Study of V934/V935 in Cancer Patients With Selected Solid Tumors (Merck) - NCT00753415-33612
Conditions: Non-Small Cell Lung - Breast Cancer - Melanoma - Upper GI Tract Carcinoma - Colon Carcinoma - Renal Cell Carcinoma - Bladder Carcinoma - Prostate Cancer
Location: Tampa, FL
- A Study of V934/V935 in Cancer Patients With Selected Solid Tumors (Merck) - NCT00753415-77024
Conditions: Non-Small Cell Lung - Breast Cancer - Melanoma - Upper GI Tract Carcinoma - Colon Carcinoma - Renal Cell Carcinoma - Bladder Carcinoma - Prostate Cancer
Location: Houston, TX
- A Study of V934/V935 in Cancer Patients With Selected Solid Tumors (Merck) - NCT00753415-80211
Conditions: Non-Small Cell Lung - Breast Cancer - Melanoma - Upper GI Tract Carcinoma - Colon Carcinoma - Renal Cell Carcinoma - Bladder Carcinoma - Prostate Cancer
Location: Denver, CO
- A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy - NCT00925600-
Conditions: Cancer - Cataract - Low Bone Mineral Density - Osteopenia - Osteoporosis - Prostate Cancer
Location: Lancaster, PA
- A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade(Registered Trademark)), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroi... -
Conditions: Breast Cancer - Colon Cancer - Prostate Cancer - Lung Cancer - Adrenal Cancer - Renal Cancer - Gastric Cancer - Ovarian Cancer - Cervical Cancer - Thyroid Cancer - Sarcoma
Location: Bethesda, MD
- A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy - NCT00887458-10021
Conditions: Prostate Cancer
Location: New York, NY
- A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy - NCT00887458-21231
Conditions: Prostate Cancer
Location: Baltimore, MD
- A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy - NCT00887458-48109
Conditions: Prostate Cancer
Location: Ann Arbor, MI
- A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy - NCT00887458-48201
Conditions: Prostate Cancer
Location: Detroit, MI
- Aberant Gene Expression Prostate Carcinoma - NCT00868803-01805
Conditions: Prostate Cancer
Location: Burlington, MA
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-
Conditions: Prostate Cancer
Location: Boston, MA
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-06520
Conditions: Prostate Cancer
Location: New Haven, CT
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-06902
Conditions: Prostate Cancer
Location: Stamford, CT
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-10065
Conditions: Prostate Cancer
Location: New York, NY
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-11040
Conditions: Prostate Cancer
Location: New Hyde Park, NY
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-13057
Conditions: Prostate Cancer
Location: East Syracuse, NY
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-13215
Conditions: Prostate Cancer
Location: Syracuse, NY
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-15213
Conditions: Prostate Cancer
Location: Pittsburgh, PA
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-19111
Conditions: Prostate Cancer
Location: Philadelphia, PA
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-21114
Conditions: Prostate Cancer
Location: Boston, MA
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-21231
Conditions: Prostate Cancer
Location: Baltimore, MD
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-23502
Conditions: Prostate Cancer
Location: Norfolk, VA
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-27607
Conditions: Prostate Cancer
Location: Raleigh, NC
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-27705
Conditions: Prostate Cancer
Location: Durham, NC
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-29210
Conditions: Prostate Cancer
Location: Columbia, SC
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-29572
Conditions: Prostate Cancer
Location: Myrtle Beach, SC
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-30084
Conditions: Prostate Cancer
Location: Atlanta, GA
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-30309
Conditions: Prostate Cancer
Location: Atlanta, GA
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-32610
Conditions: Prostate Cancer
Location: Gainesville, FL
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-33486
Conditions: Prostate Cancer
Location: Boca Raton, FL
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-33916
Conditions: Prostate Cancer
Location: Fort Myers, FL
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-35205
Conditions: Prostate Cancer
Location: Birmingham, AL
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-37203
Conditions: Prostate Cancer
Location: Nashville, TN
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-37404
Conditions: Prostate Cancer
Location: Chattanooga, TN
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-44718
Conditions: Prostate Cancer
Location: Canton, OH
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-48201
Conditions: Prostate Cancer
Location: Detroit, MI
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-53792
Conditions: Prostate Cancer
Location: Madison, WI
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-59107
Conditions: Prostate Cancer
Location: Billings, MT
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-68121
Conditions: Prostate Cancer
Location: Omaha, NE
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-70006
Conditions: Prostate Cancer
Location: Metairie, LA
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-70112
Conditions: Prostate Cancer
Location: New Orleans, LA
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-75246
Conditions: Prostate Cancer
Location: Dallas, TX
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-75390
Conditions: Prostate Cancer
Location: Dallas, TX
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-77030
Conditions: Prostate Cancer
Location: Houston, TX
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-78229
Conditions: Prostate Cancer
Location: San Antonio, TX
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-80045
Conditions: Prostate Cancer
Location: Aurora, CO
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-85715
Conditions: Prostate Cancer
Location: Tuscon, AZ
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-85724
Conditions: Prostate Cancer
Location: Tuscon, AZ
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-89135
Conditions: Prostate Cancer
Location: Las Vegas, NV
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-89169
Conditions: Prostate Cancer
Location: Las Vegas, NV
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-90025
Conditions: Prostate Cancer
Location: Los Angeles, CA
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-90033
Conditions: Prostate Cancer
Location: Los Angeles, CA
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-90095A
Conditions: Prostate Cancer
Location: Los Angeles, CA
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-90095B
Conditions: Prostate Cancer
Location: Los Angeles, CA
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-90292
Conditions: Prostate Cancer
Location: Marina Del Rey, CA
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-90706
Conditions: Prostate Cancer
Location: Bellflower, CA
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-92123
Conditions: Prostate Cancer
Location: San Diego, CA
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-94115A
Conditions: Prostate Cancer
Location: San Francisco, CA
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-94115B
Conditions: Prostate Cancer
Location: San Francisco, CA
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-94305
Conditions: Prostate Cancer
Location: Stanford, CA
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-95817
Conditions: Prostate Cancer
Location: Sacramento, CA
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-96819
Conditions: Prostate Cancer
Location: Honolulu, HI
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-97239
Conditions: Prostate Cancer
Location: Portland, OR
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-98017
Conditions: Prostate Cancer
Location: Seattle, WA
- Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer - NCT00887198-98109
Conditions: Prostate Cancer
Location: Seattle, WA
- Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer - NCT00295802-
Conditions: Prostate Cancer
Location: Danville, PA
- Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer - NCT00295802-07601
Conditions: Prostate Cancer
Location: Hackensack, NJ
- Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer - NCT00295802-15212
Conditions: Prostate Cancer
Location: Pittsburg, PA
- Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer - NCT00295802-19107
Conditions: Prostate Cancer
Location: Philadelphia, PA
- Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer - NCT00295802-23235
Conditions: Prostate Cancer
Location: Richmond, VA
- Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer - NCT00295802-27710
Conditions: Prostate Cancer
Location: Durham, NC
- Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer - NCT00295802-34474
Conditions: Prostate Cancer
Location: Ocala, FL
- Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer - NCT00295802-37232
Conditions: Prostate Cancer
Location: Nashville, TN
- Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer - NCT00295802-44195
Conditions: Prostate Cancer
Location: Cleveland, OH
- Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer - NCT00295802-53226
Conditions: Prostate Cancer
Location: Milwaukee, WI
- Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer - NCT00295802-76017
Conditions: Prostate Cancer
Location: Arlington, TX
- Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer - NCT00295802-76508
Conditions: Prostate Cancer
Location: Temple, TX
- Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer - NCT00295802-77230
Conditions: Prostate Cancer
Location: Houston, TX
- Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer - NCT00295802-80010
Conditions: Prostate Cancer
Location: Aurora, CO
- Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer - NCT00295802-91006
Conditions: Prostate Cancer
Location: Arcadia, CA
- Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer - NCT00295802-93720
Conditions: Prostate Cancer
Location: Fresno, CA
- Active Surveillance in Prostate Cancer - NCT00490763-77030
Conditions: Prostate Cancer
Location: Houston, TX
- Acupuncture Treatment for Hot Flashes Study - NCT00421902-11215
Conditions: Prostate Cancer
Location: Brooklyn, NY
- Adjuvant Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic T2-T3N0M0 Prostate Cancer - NCT00669162-90033
Conditions: Prostate Cancer
Location: Los Angeles, CA
- Alpharadin™ Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton - NCT00748046-10021
Conditions: Prostate Cancer - Metastases - Pharmacokinetics
Location: New York, NY
- AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer - NCT00770848-
Conditions: Cancer - Castrate-Resistant Prostate Cancer - Mestastatic Prostate Cancer - Prostate Cancer
Location: Seattle, WA
- An Open Label Phase I Study to Eval the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing ... -
Conditions: Prostate Cancer - Breast Cancer - Lung Cancer - Colorectal Cancer - Head and Neck Cancer
Location: Bethesda, MD
- An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG 162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-Metastatic Prostate Cancer - NCT00838201-
Conditions: Cancer - Carcinoma - Castrate-Resistant Prostate Cancer - Prostate Cancer - Tumors
Location: Seattle, WA
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-01605
Conditions: Prostate Cancer
Location: Worcester, MA
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-01702
Conditions: Prostate Cancer
Location: Framingham, MA
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-01742
Conditions: Prostate Cancer
Location: Concord, MA
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-01805
Conditions: Prostate Cancer
Location: Burlington, MA
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-01842
Conditions: Prostate Cancer
Location: Lawrence, MA
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-02118
Conditions: Prostate Cancer
Location: Boston, MA
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-02169
Conditions: Prostate Cancer
Location: Quincy, MA
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-02180
Conditions: Prostate Cancer
Location: Stoneham, MA
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-02190
Conditions: Prostate Cancer
Location: Weymouth, MA
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-07018
Conditions: Prostate Cancer
Location: East Orange, NJ
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-07902
Conditions: Prostate Cancer
Location: Summit, NJ
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-07962
Conditions: Prostate Cancer
Location: Morristown, NJ
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-08690
Conditions: Prostate Cancer
Location: Hamilton, NJ
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-08822
Conditions: Prostate Cancer
Location: Flemington, NJ
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-08903
Conditions: Prostate Cancer
Location: New Brunswick, NJ
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-10016
Conditions: Prostate Cancer
Location: New York, NY
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-10032
Conditions: Prostate Cancer
Location: New York, NY
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-10940
Conditions: Prostate Cancer
Location: Middletown, NY
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-11203A
Conditions: Prostate Cancer
Location: Brooklyn, NY
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-11203B
Conditions: Prostate Cancer
Location: Brooklyn, NY
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-12801
Conditions: Prostate Cancer
Location: Glens Falls, NY
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-13210
Conditions: Prostate Cancer
Location: Syracuse, NY
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-14263
Conditions: Prostate Cancer
Location: Buffalo, NY
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-15801
Conditions: Prostate Cancer
Location: Dubois, PA
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-16801
Conditions: Prostate Cancer
Location: State College, PA
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-17405
Conditions: Prostate Cancer
Location: York, PA
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-17822
Conditions: Prostate Cancer
Location: Danville, PA
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-18201
Conditions: Prostate Cancer
Location: Hazleton, PA
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-18711
Conditions: Prostate Cancer
Location: Wilkes-Barre, PA
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-19001
Conditions: Prostate Cancer
Location: Abington, PA
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-19010
Conditions: Prostate Cancer
Location: Bryn Mawr, PA
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-19096A
Conditions: Prostate Cancer
Location: Wynnewood, PA
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-19096B
Conditions: Prostate Cancer
Location: Wynnewood, PA
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-19104
Conditions: Prostate Cancer
Location: Philadelphia, PA
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-19111
Conditions: Prostate Cancer
Location: Philadelphia, PA
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-19301
Conditions: Prostate Cancer
Location: Paoli, PA
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-19380
Conditions: Prostate Cancer
Location: West Chester, PA
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-19605
Conditions: Prostate Cancer
Location: Reading, PA
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-20007
Conditions: Prostate Cancer
Location: Washington, DC
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-21229
Conditions: Prostate Cancer
Location: Baltimore, MD
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-21231
Conditions: Prostate Cancer
Location: Baltimore, MD
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-25304
Conditions: Prostate Cancer
Location: Charleston, WV
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-27534A
Conditions: Prostate Cancer
Location: Goldsboro, NC
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-27534B
Conditions: Prostate Cancer
Location: Goldsboro, NC
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-28233
Conditions: Prostate Cancer
Location: Charlotte, NC
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-28501
Conditions: Prostate Cancer
Location: Kinston, NC
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-28791
Conditions: Prostate Cancer
Location: Hendersonville, NC
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-29615
Conditions: Prostate Cancer
Location: Greenville, SC
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-30501
Conditions: Prostate Cancer
Location: Gainesville, GA
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-32224
Conditions: Prostate Cancer
Location: Jacksonville, FL
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-32610
Conditions: Prostate Cancer
Location: Gainesville, FL
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-33136
Conditions: Prostate Cancer
Location: Miami, FL
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-33140
Conditions: Prostate Cancer
Location: Miami Beach, FL
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-33308
Conditions: Prostate Cancer
Location: Fort Lauderdale, FL
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-33458
Conditions: Prostate Cancer
Location: Jupiter, FL
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-36608
Conditions: Prostate Cancer
Location: Mobile, AL
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-37203
Conditions: Prostate Cancer
Location: Nashville, TN
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-37208
Conditions: Prostate Cancer
Location: Nashville, TN
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-37920
Conditions: Prostate Cancer
Location: Knoxville, TN
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-40292
Conditions: Prostate Cancer
Location: Louisville, KY
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-44109
Conditions: Prostate Cancer
Location: Cleveland, OH
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-44195
Conditions: Prostate Cancer
Location: Cleveland, OH
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-44203
Conditions: Prostate Cancer
Location: Barberton, OH
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-44309
Conditions: Prostate Cancer
Location: Akron, OH
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-44710
Conditions: Prostate Cancer
Location: Canton, OH
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-45267
Conditions: Prostate Cancer
Location: Cincinnati, OH
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-45801
Conditions: Prostate Cancer
Location: Lima, OH
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-46202A
Conditions: Prostate Cancer
Location: Indianapolis, IN
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-46202B
Conditions: Prostate Cancer
Location: Indianapolis, IN
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-46202C
Conditions: Prostate Cancer
Location: Indianapolis, IN
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-46845
Conditions: Prostate Cancer
Location: Fort Wayne, IN
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-48060
Conditions: Prostate Cancer
Location: Port Huron, MI
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-48075
Conditions: Prostate Cancer
Location: Southfield, MI
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-48093
Conditions: Prostate Cancer
Location: Warren, MI
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-48106A
Conditions: Prostate Cancer
Location: Ann Arbor, MI
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-48106B
Conditions: Prostate Cancer
Location: Ann Arbor, MI
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-48109
Conditions: Prostate Cancer
Location: Ann Arbor, MI
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-48123
Conditions: Prostate Cancer
Location: Dearborn, MI
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-48154
Conditions: Prostate Cancer
Location: Livonia, MI
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-48236
Conditions: Prostate Cancer
Location: Grosse Pointe Woods, MI
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-48341
Conditions: Prostate Cancer
Location: Pontiac, MI
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-48503A
Conditions: Prostate Cancer
Location: Flint, MI
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-48503B
Conditions: Prostate Cancer
Location: Flint, MI
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-48601
Conditions: Prostate Cancer
Location: Saginaw, MI
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-48912
Conditions: Prostate Cancer
Location: Lansing, MI
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-49001
Conditions: Prostate Cancer
Location: Kalamazoo, MI
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-49007A
Conditions: Prostate Cancer
Location: Kalamazoo, MI
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-49007B
Conditions: Prostate Cancer
Location: Kalamazoo, MI
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-49431
Conditions: Prostate Cancer
Location: Escanaba, MI
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-49801
Conditions: Prostate Cancer
Location: Iron Mountain, MI
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-50309A
Conditions: Prostate Cancer
Location: Des Moines, IA
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-50309B
Conditions: Prostate Cancer
Location: Des Moines, IA
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-50309C
Conditions: Prostate Cancer
Location: Des Moines, IA
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-50314A
Conditions: Prostate Cancer
Location: Des Moines, IA
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-50314B
Conditions: Prostate Cancer
Location: Des Moines, IA
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-50316
Conditions: Prostate Cancer
Location: Des Moines, IA
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-50325
Conditions: Prostate Cancer
Location: Clive, IA
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer - NCT00309985-50401
Conditions: Prostate Cancer
Location: Mason City, IA
|
|
|
|
|
Didn't find what you were looking for? Try these alternatives:
Become A Member: To be notified of upcoming clinical trials in your
area please create a free member account.
Browse Studies: If you would like to browse all featured clinical trials
please Browse Studies.
Message Board: Join the discussion in our Health
and Clinical Trials Message Board.
|
|
|